Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study
Journal of the American Academy of Dermatology | 25 Sep 2016
A Blauvelt, K Reich, TF Tsai, S Tyring, F Vanaclocha, K Kingo, M Ziv, A Pinter, R Vender, S Hugot, R You, M Milutinovic and D Thaçi
Secukinumab demonstrated superior efficacy to ustekinumab at week 4 and week 16 of the CLEAR study, with comparable safety, in subjects with moderate-to-severe plaque psoriasis.
* Data courtesy of Altmetric.com